Angle PLC Issue of Equity and Total Voting Rights (1660X)
August 26 2015 - 8:48AM
UK Regulatory
TIDMAGL
RNS Number : 1660X
Angle PLC
26 August 2015
ANGLE plc
("ANGLE" or "the Company")
Issue of Equity and Total Voting Rights
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech
company, announces that it has received notice from a former
employee to exercise options over 4,000 ordinary shares of 10p each
in the Company.
Accordingly the Company has allotted 4,000 new ordinary shares
of 10p each ("New Ordinary Shares") in the capital of the Company.
The New Ordinary Shares rank pari passu with the existing ordinary
shares in the Company. An application has been made for the New
Ordinary Shares to be admitted to trading on AIM and admission is
expected to take place at 8.00 am on 2 September 2015. Following
this allotment, the total issued share capital of the Company is
58,978,338 ordinary shares. The figure of 58,978,338 Ordinary
Shares may be used by shareholders as the denominator for the
calculation by which they will determine if they are required to
notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure and Transparency Rules.
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
Notes for editors
About ANGLE plc
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology, known as the Parsortix
system, harvests the cells of interest through a liquid biopsy,
with the patient only experiencing a simple blood test. Parsortix
is the subject of two granted US patents, granted patents in China
and Australia and three extensive families of patents being
progressed worldwide. The system is based on a microfluidic device
that captures cells based on a combination of their size and
compressibility. The Parsortix system is established with strong
positive evaluations from leading cancer research centres and is
working with these cancer centres to demonstrate key applications.
Parsortix has a CE Mark for Europe and FDA authorisation is in
process for the US.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The Parsortix system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
In addition to cancer, the Parsortix technology has the
potential for deployment with several other important cell types in
the future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For more
information visit www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUACRUPAGPQ
(END) Dow Jones Newswires
August 26, 2015 08:48 ET (12:48 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Angle (LSE:AGL)
Historical Stock Chart
From Sep 2023 to Sep 2024
